Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters-Reference-Cited by-同舟云学术

Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters

Author:

Millar B. C.¹²,McCaughan J.³,Rendall J. C.⁴,Downey D. G.⁴⁵,Moore J. E.¹²⁴⁵

Affiliation:

1. Northern Ireland Public Health Laboratory; Department of Bacteriology; Belfast City Hospital; Belfast UK

2. School of Biomedical Sciences; Ulster University; Coleraine UK

3. Department of Medical Microbiology; Belfast Health & Social Care Trust (BHSCT), Kelvin Building; Royal Group of Hospitals; Belfast UK

4. Northern Ireland Regional Adult Cystic Fibrosis Centre, Level 8; Belfast City Hospital; Belfast UK

5. Centre for Experimental Medicine; Queen's University; Belfast UK

Funder

Vertex Pharmaceuticals

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

Reference8 articles.

2. Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis;O'Reilly;Drug Des Devel Ther,2013

3. Relative Resistance Index (RRI)-a scoring system for antibiotic resistance in Pseudomonas aeruginosa;Ewing;Br J Biomed Sci,2017

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献